Kobiolabs gets Chinese patent for obesity treatment strain
Akkermansia muciniphila KBL983 was shown to induce GLP-1 expression and increase brown fat activity
By Jan 17, 2024 (Gmt+09:00)
Hankook Tire buys $1 bn Hanon Systems stake from Hahn & Co.
S.Korea's LS Materials set to boost earnings ahead of IPO process
NPS to hike risky asset purchases under simplified allocation system
Aman, Rosewood, Banyan, IHG rush to open luxury hotels in Seoul
Osstem to buy Brazil’s No. 3 dental implant maker Implacil
South Korean microbiome-based new drug development company Kobiolabs Co. announced on Wednesday that it has a patent for its obesity treatment strain Akkermansia muciniphila KBL983 in China.
KBL983 is derived from the human microbiome. Kobiolabs has discovered that it induces the expression of the key metabolic hormone glucagon-like peptide-1 (GLP-1) and increases the activity of brown fat, which is known to suppress obesity.
Previously, key research findings on KBL983 were published in Nature Microbiology, a premier international journal showcasing cutting-edge research in all areas of microbiology.
Kobiolabs is currently developing an obesity treatment using a combination of strains, including KBL983, under the National New Drug Development Project.
Write to In-Hyuk Park at hyuk@hankyung.com
-
Bio & PharmaKobiolabs gets US patent for oral obesity drug candidate
Jan 10, 2024 (Gmt+09:00)
1 Min read -
Bio & PharmaKobiolabs, Kakao Healthcare to explore microbiome-based precision medicine solutions
Mar 29, 2023 (Gmt+09:00)
1 Min read